All articles by Drug Target Review – Page 23
-
NewsNew therapy for incurable brain disease heads to clinical trials
SynaptixBio has selected its lead drug candidate, SB H-19642, for clinical trials to treat H-ABC - a rare, fatal neurodegenerative disease with no current cure.
-
NewsDual-action therapy clears MDR bacteria in preclinical models
Centauri Therapeutics has published data showing that CTX-09’s ability effectively clears drug-resistant Gram-negative bacteria through a novel dual mechanism, marking a promising development for new infection therapies.
-
ArticleWhy playing it safe is slowing down drug discovery
President Trump’s proposed drug pricing reforms are putting pressure on early-stage discovery. To keep pace, teams must rethink how they manage risk, resources and collaboration.
-
News3D model reveals hidden drivers of smell regeneration
Scientists have developed a simple- 3D mouse tissue model to study how the nose regenerates smell-sensing neurons. The goal is to create an organoid system that can be used to screen potential therapies for smell loss.
-
NewsOrganoids take on ESCC’s toughest tumours
A new study at Science Tokyo has developed patient-derived organoids to better understand and combat resistance in oesophageal squamous cell carcinoma (ESCC).
-
NewsReelin identified as key marker of cocaine-activated brain cells
Researchers at the University of Alabama have identified reelin, a glycoprotein known for its role in brain development, as a key regulator of neurons in the brain's reward centre, potentially making way for targeted therapies against cocaine use.
-
News
Stanford grows vascularised mini-organs
Stanford scientists have successfully grown heart and liver organoids that include functioning blood vessels. This breakthrough overcomes a major size and maturity barrier, which could advance disease modelling and regenerative therapies in the future.
-
NewsSB000: a safer path to anti-aging therapies
Shift Bioscience has announced new aging research, highlighting the discovery of SB000. This novel single-gene target reverses cellular aging without activating dangerous pluripotency pathways.
-
NewsEngineered DNA aptamers outsmart viral infection pathways
EPFL scientists have engineered virus-inspired DNA aptamers that bind infection targets with record selectivity. This innovation could change how we diagnose and treat infectious diseases.
-
ArticleA global push for better animal welfare in research
What does ethical research look like in drug discovery today? In this interview, Charles River’s Executive Director of Global Animal Welfare shares how global standards, the 3Rs and her own path as a woman in STEM are shaping efforts to reduce animal use in science.
-
NewsHow one carbon atom is changing drug development
Researchers at the University of Oklahoma have found a way to improve drugs by adding just one carbon atom. This simple change could speed up drug discovery and lower costs.
-
NewsAI just made protein design smarter and faster
Meet the AI tool that creates proteins that fold better, bind tighter and perform more reliably. Find out why it matters for next-generation medicines.
-
NewsInside the immune ‘handbook’ set to disrupt fibrosis research
Nearly a billion people are affected by chronic organ scarring, yet treatments remain limited. Now, Duke-NUS researchers have compiled a scientific ‘handbook’ of immune cell insights that could fast-track breakthroughs in fibrosis therapy.
-
ArticleNew tRNA tech aims to rewrite rare disease treatment
Alltrna is redefining the future of rare disease treatment with engineered tRNA therapeutics that target genetic mutations - not just individual diseases. CEO Michelle Werner shares how this bold, mutation-driven approach could unlock universal treatments for thousands of patients long overlooked by traditional medicine.
-
NewsStatins repurposed for sepsis show life-saving potential
A new study suggests statins, cheap and widely used cholesterol drugs, could be repurposed to reduce the risk of death from sepsis. Researchers reported a 39 percent drop in 28-day mortality, highlighting their potential role in critical care.
-
ArticleShifting the ADC focus from antibody to payload
While ADCs continue to attract attention in oncology, many developers remain focused on antibodies – overlooking the critical role of payload design. At Sygnature Discovery, Dr Joshua Greally is leading a shift in perspective, advocating for a payload-first approach through the company’s new platform, NewPath ADC. In this interview, he ...
-
ArticleWhy radiopharmaceuticals are gaining ground in the fight against cancer
Radiopharmaceuticals represent a rapidly advancing field in oncology, using radioactive compounds to both detect and treat cancer at the molecular level. This article explores how targeted radiation is improving patient outcomes while reducing systemic toxicity.
-
NewsBCG alters bone marrow to strengthen anti-cancer response
A new study reveals that BCG, a decades-old bladder cancer treatment, reprograms the immune system at the bone marrow level, offering a new perspective into how this immunotherapy boosts the body’s defence against cancer.
-
NewsStudy identifies safer target for dopamine-linked disorders
A rare genetic glitch causes dopamine to leak in the brain - now researchers may have found a way to stop it, without the risks of current treatments.
-
NewsScientists create advanced 3D liver model mimicking real tissue
Scientists have developed a 3D liver model, known as the periportal assembloid. This model replicates the liver’s complex structure and bile transport system, enabling more precise study of disease progression.